These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31713086)

  • 21. Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation.
    Nam KW; Kwon HM; Lee YS; Won SH; Moon HS; Park JH
    Sci Rep; 2024 Apr; 14(1):9838. PubMed ID: 38684879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
    Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
    J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.
    Patti G; Di Gioia G; Cavallari I; Nenna A
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
    Barbarawi M; Barbarawi O; Corcoran J; Obeidat K; Al-Abdouh A; Mhanna M; Al Kasasbeh M; Pickett CC
    Curr Probl Cardiol; 2022 Nov; 47(11):101346. PubMed ID: 35932849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
    Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis.
    Malhotra K; Ishfaq MF; Goyal N; Katsanos AH; Parissis J; Alexandrov AW; Alexandrov AV; Tsivgoulis G
    Neurology; 2019 May; 92(21):e2421-e2431. PubMed ID: 31068485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.
    Dentali F; Riva N; Crowther M; Turpie AG; Lip GY; Ageno W
    Circulation; 2012 Nov; 126(20):2381-91. PubMed ID: 23071159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies.
    Chen Y; Mao M; Chang J; Yan J; Yang T; Liu Y; Luo M; Hu Y; Yang Q; Zhou L; Ma K
    Eur J Clin Pharmacol; 2021 Jun; 77(6):849-857. PubMed ID: 33791828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients (≥80 years of age) with atrial fibrillation: systematic review and meta-analysis.
    Kang F; Su L; Fan S; Lv L; Luo B
    Intern Med J; 2023 Sep; 53(9):1524-1532. PubMed ID: 37178051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Aug; 72(2):105-112. PubMed ID: 29519547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis.
    Li Z; Zheng Y; Li D; Wang X; Cheng S; Luo X; Wen A
    Anatol J Cardiol; 2022 Jun; 26(6):424-433. PubMed ID: 35703478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies.
    Guo Z; Ding X; Ye Z; Chen W; Chen Y
    Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual Aid Tool to Improve Decision Making in Anticoagulation for Stroke Prevention.
    Saposnik G; Joundi RA
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2380-5. PubMed ID: 27318647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
    Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.